To model the heterogenous expression of GPC2 and CD276, which can result in tumor evasion in single-target CAR T cell therapies, we used a mixture of NALM6 cells stably expressing either GPC2 or CD276 and treated them with BiCisCARs or single antigen–targeting CARs (Figure 9A and Supplemental Figure 11A). This evidence concerns the gene GPC2 and neoplasm.